HAVN Life Ships First White Label Order to Distribution Partner Woke Pharmaceuticals in Australia May 2, 2022
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT Apr 13, 2022
Revive Therapeutics May Seek FDA Approval To Amend Phase 3 Endpoints In Bucillamine Trial To A Symptoms Focus Apr 11, 2022
